Last reviewed · How we verify
ARQ-151 cream 0.3%
ARQ-151 is a topical phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory cytokine production in skin.
ARQ-151 is a topical phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory cytokine production in skin. Used for Atopic dermatitis, Plaque psoriasis.
At a glance
| Generic name | ARQ-151 cream 0.3% |
|---|---|
| Also known as | Topical roflumilast |
| Sponsor | Arcutis Biotherapeutics, Inc. |
| Drug class | Phosphodiesterase 4 (PDE4) inhibitor |
| Target | PDE4 |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
PDE4 inhibition increases intracellular cAMP levels in immune and inflammatory cells, suppressing the production of pro-inflammatory cytokines such as TNF-α and IL-23. This mechanism reduces skin inflammation and is particularly effective in atopic dermatitis and other inflammatory skin conditions where PDE4 plays a key pathogenic role.
Approved indications
- Atopic dermatitis
- Plaque psoriasis
Common side effects
- Application site irritation
- Application site burning
- Pruritus
Key clinical trials
- Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis (PHASE3)
- Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215) (PHASE2)
- Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216) (PHASE2)
- Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis (PHASE3)
- Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis (PHASE3)
- The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis (PHASE2)
- Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis (PHASE2)
- Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque Psoriasis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ARQ-151 cream 0.3% CI brief — competitive landscape report
- ARQ-151 cream 0.3% updates RSS · CI watch RSS
- Arcutis Biotherapeutics, Inc. portfolio CI